Pathology: breast cancer - adjuvant; la/mBC - HER2 positive - 2nd Line (L2);
| breast cancer - adjuvant | la/mBC - HER2 positive - 2nd Line (L2) | ||||
| ExteNET, 2016 | ExteNET, 2016 | NALA (brain metastases), 2020 | NALA, 2020 | ||
| neratinib plus capecitabine | 2 | T1 | T1 | ||
| neratinib | 2 | T1 | T1 | ||
| lapatinib plus capecitabine | 0 | T0 | T0 | ||
| placebo | 0 | T0 | T0 | ||